The study is aimed at assessing the safety and immunogenicity of HCV prime-boost vaccinations ChAd3-hliNSmut and MVA-hliNSmut, administered intramuscularly in healthy volunteers and DAA treated patients.
There is a tremendous shortage of kidneys needed for transplants. In a first of its kind study, a hepatitis C (HCV) infected kidney is being transplanted into HCV-negative persons and being treated with Zepatier. Treatment is occurring after a single kidney transplant.
University of Pennsylvania: Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Kidney Transplants From Hepatitis C-Positive Donors (HCV)
To read the entire clinical trial description, click here…
View an inspirational video from the University of Pennsylvania, click here….